Succinobucol

Drug Profile

Succinobucol

Alternative Names: AGI-1067

Latest Information Update: 26 Jun 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AtheroGenics
  • Class Anti-ischaemics; Antihyperlipidaemics; Phenols
  • Mechanism of Action Antioxidants; Lipid peroxidation inhibitors; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 09 Jun 2009 Pharmacodynamics data from an in vitro study presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
  • 07 Oct 2008 AtheroGenics files for chapter 11 bankruptcy in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top